Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia.
Although micafungin pharmacokinetic values were comparable between younger (<5 years) and older children (≥5 years) with candidemia and invasive candidiasis, younger children had a lower peak plasma micafungin concentration, lower micafungin exposure and larger micafungin clearance. Half-life remained unchanged with repeated dosing. Metabolite plasma concentrations remained low in older children; however, metabolite M-5 concentrations were higher in younger children.
Astellas Pharma Europe Ltd, Staines, Middlesex, United Kingdom. nas.undre@eu.astellas.com
Nasrullah A
NA
Undre
Paul
P
Stevenson
Antonio
A
Freire
Antonio
A
Arrieta
D000293:Adolescent; D000367:Age Factors; D000935:Antifungal Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D058387:Candidemia / Q000188:drug therapy*; D058365:Candidiasis, Invasive / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D054714:Echinocandins / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D007223:Infant; D055666:Lipopeptides / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008297:Male; D008657:Metabolic Clearance Rate; D000077551:Micafungin
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D000077551:Micafungin